Socio-demographic and clinical features of Irish iatrogenic hepatitis C patients: a cross-sectional survey

Pain and opioid use in chronic liver disease

BACKGROUND

Pain is common in patients with liver disease, difficult to treat, and poorly understood.

AIMS

The aim of this study was to determine factors associated with pain and prescription opioid use in a large cohort of patients with confirmed chronic liver disease.

METHODS

This was a retrospective cohort study of consecutive patients with chronic liver disease visiting a tertiary-care hepatology clinic. Pain was determined by self-report and rated numerically from 0 to 10. Symptoms of mood and sleep disorders and emotional distress were based on a symptom checklist. Etiology and stage of liver disease and use of prescribed opioids were abstracted from the electronic medical record. Logistic regression was used to establish factors associated with pain and prescription opioid use.

RESULTS

Among 1,286 patients with chronic liver disease, 34 % had pain and 25 % used opioids. The strongest predictor of pain in multivariate modeling was emotional distress (OR 3.66, 95 % CI 2.40-5.64), followed by non-white race (OR 1.87, 95 % CI 1.24-2.79), mood symptoms (OR 1.47, 95 % CI 1.04-2.07), sleep disturbance/fatigue (OR 1.70, 95 % CI 1.24-2.32), and advanced liver disease (Child class B: OR 1.73, 95 % CI 1.15-2.60; Child class C: OR 2.78, 95 % CI 1.49-5.24) compared to no cirrhosis. Emotional distress, mood-related symptoms, and advanced liver disease were also significant predictors of prescription opioid use, as were age, nicotine use, and etiology of liver disease.

CONCLUSIONS

This large cohort study demonstrates the high prevalence of pain and opioid use in chronic liver disease. While disease variables contribute to pain, psychological symptoms were most strongly associated with pain and opioid use, providing rationale and target for therapeutic interventions.

Management of the extrahepatic symptoms of chronic hepatitis C: feasibility of a randomized controlled trial of exercise

OBJECTIVE

The aim of this study was to explore the feasibility and the efficacy of a physiotherapy-led exercise program in changing the health status of a sample of patients with chronic hepatitis C.

DESIGN

A single-blind randomized controlled trial was conducted in a sample of patients with iatrogenically acquired hepatitis C in Ireland. Twenty-two participants were recruited and randomly assigned to exercise (n = 10) and control (n = 12) groups. Both groups received a generic exercise advice leaflet, and the exercise group attended 12 exercise sessions for 6 wks. A battery of physical performance measures and patient-reported outcome measures were assessed at baseline and 6 wks, with 1-yr follow-up of the self-reported measures.

RESULTS

Significant group by time interactions during the 6-wk period were found for pain (F(1,20) = 5.15, P = 0.034), grip strength (F(1,20) = 5.94, P = 0.024), aerobic capacity (F(1,20) = 5.73, P = 0.024), and depression (F(1,20) = 6.16, P = 0.022), with the exercise group showing greater positive change. The exercise group also had superior gains in the 36-Item Short-Form Health Survey vitality and social function scores (P < 0.05). The short-term gains were not sustained at 1 yr.

CONCLUSIONS

This pilot study shows the feasibility of exercise in hepatitis C management, improving physical fitness, psychologic function, and quality-of-life without worsening symptoms in the short term.

The relationship between tumor necrosis factor-α polymorphisms and hepatitis C virus infection: a systematic review and meta-analysis

BACKGROUND AND AIMS

Hepatitis C virus (HCV) is now recognized as one of the major causes of chronic liver disease. It is also one of the most common complications in maintenance hemodialysis (HD) patients. Tumor necrosis factor (TNF)-α promoter polymorphisms are observed to modulate TNF-α levels and thought to have an effect on susceptibility to HCV infection and the virus clearance, but the results are inconsistent. In this study, a systematic review and meta-analysis of the published data was performed to evaluate the relationship between the TNF-α-238, -308 polymorphisms and HCV infection.

METHODS

A total of 15 studies published were analyzed, which were indexed from PubMed, Embase, and CNKI databases (up to December 2010). All the data were analyzed using RevMan 4.2 software. Odds ratios (OR) and confidence intervals (95% CI) were calculated by fixed or random-effects models. Heterogeneity and publication bias across the studies were also explored.

RESULTS

The data showed no significant association between TNF-α-308, -238 gene polymorphisms and the susceptibility to HCV infection in the global group (p = 0.28, p = 0.38, respectively) and the sub-groups (European, American, African, and Asian). Besides, the distributions of TNF-α-308, -238 A/G alleles were also not significantly different between the persistent infection group and the spontaneous clearance group (p = 0.64, p = 0.75, respectively).

CONCLUSION

TNF-α-238, -308 gene polymorphisms might have no effect on susceptibility to HCV infection and the virus clearance. The findings of this meta-analysis have implications in the optimal prevention of HCV in HD patients and in the guidance of future research.